KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Convertible Debt (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Convertible Debt for 17 consecutive years, with $597.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Convertible Debt changed 0.34% year-over-year to $597.2 million, compared with a TTM value of $597.2 million through Dec 2025, changed 0.34%, and an annual FY2025 reading of $597.2 million, changed 0.34% over the prior year.
  • Convertible Debt was $597.2 million for Q4 2025 at Biomarin Pharmaceutical, roughly flat from $596.7 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $1.1 billion in Q2 2024 and bottomed at $594.6 million in Q3 2024.
  • Average Convertible Debt over 5 years is $936.5 million, with a median of $1.1 billion recorded in 2021.
  • The sharpest move saw Convertible Debt increased 26.21% in 2021, then crashed 45.25% in 2025.
  • Year by year, Convertible Debt stood at $1.1 billion in 2021, then grew by 0.37% to $1.1 billion in 2022, then rose by 0.36% to $1.1 billion in 2023, then plummeted by 45.25% to $595.1 million in 2024, then rose by 0.34% to $597.2 million in 2025.
  • Business Quant data shows Convertible Debt for BMRN at $597.2 million in Q4 2025, $596.7 million in Q3 2025, and $596.2 million in Q2 2025.